Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Details : Zelenirstat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2024
Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
Details : PCLX-001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2021
Lead Product(s) : PCLX-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Canadian Angel Investors
Deal Size : $3.9 million
Deal Type : Financing
Pacylex Raises US $3.9 Million To Advance New Cancer Therapy PCLX-001 Towards Clinical Trials
Details : These funds will support advancing the Company’s first product, PCLX-001, to clinical trials anticipated to start later this year.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 04, 2020
Lead Product(s) : PCLX-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Canadian Angel Investors
Deal Size : $3.9 million
Deal Type : Financing
Reset All
